SG Americas Securities
FDMT icon

SG Americas Securities’s 4D Molecular Therapeutics FDMT Stock Holding History

SG Americas Securities’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,531
Closed -$116K – 3386
2025
Q4 		$116K Buy
+15,531
New +$158K ﹤0.01% 3166
2025
Q3 		– Sell
-17,193
Closed -$64K – 3436
2025
Q2 		$64K Sell
17,193
-5,681
-25% -$20K ﹤0.01% 2728
2025
Q1 		$74K Sell
22,874
-7,010
-23% -$33K ﹤0.01% 3140
2024
Q4 		$166K Buy
29,884
+174
+0.6% +$1.36K ﹤0.01% 2324
2024
Q3 		$321K Buy
+29,710
New +$493K ﹤0.01% 2083
2024
Q2 		– Sell
-4,583
Closed -$146K – 2995
2024
Q1 		$146K Sell
4,583
-22,316
-83% -$569K ﹤0.01% 2229
2023
Q4 		$545K Buy
26,899
+14,645
+120% +$193K 0.01% 1423
2023
Q3 		$156K Buy
+12,254
New +$205K ﹤0.01% 2473
2023
Q2 		– Sell
-6,275
Closed -$108K – 2564
2023
Q1 		$108K Sell
6,275
-2,356
-27% -$45.8K ﹤0.01% 2851
2022
Q4 		$192K Sell
8,631
-12,606
-59% -$195K ﹤0.01% 2225
2022
Q3 		$171K Buy
21,237
+5,928
+39% +$53.7K ﹤0.01% 2439
2022
Q2 		$107K Buy
15,309
+6,967
+84% +$67.7K ﹤0.01% 3085
2022
Q1 		$126K Sell
8,342
-1,338
-14% -$21K ﹤0.01% 2673
2021
Q4 		$212K Sell
9,680
-4,517
-32% -$111K ﹤0.01% 2642
2021
Q3 		$383K Buy
14,197
+4,932
+53% +$141K ﹤0.01% 2733
2021
Q2 		$223K Buy
+9,265
New +$284K ﹤0.01% 2288
2021
Q1 		– Sell
-33,680
Closed -$1.4M – 3362
2020
Q4 		$1.4M Buy
+33,680
New +$1.39M 0.01% 1328

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SG Americas Securities's FDMT Position: Q1 2026 in Review

SG Americas Securities sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 15,531 shares — an estimated $116K sold.

SG Americas Securities first reported a position in FDMT in Q4 2020 and held it in 17 quarters. The position peaked at $1.4M in Q4 2020. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • SG Americas Securities reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 15,531 4D Molecular Therapeutics shares in Q1 2026, an estimated $116K.
  • SG Americas Securities first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 17 quarters.
  • SG Americas Securities's 4D Molecular Therapeutics position peaked at $1.4M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.